TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03131648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study: NCT01141192

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3, cholecalciferol
Description: 1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive comparator
Description: The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
Study: NCT00563784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily for 7 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 AUC by vein weekly for 7 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45 mg/m\^2 by vein weekly for 7 Weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 63 GY/35 fractions for 7 weeks (+/- 5 days)
Study: NCT03966976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG monitoring & record
Description: This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
Study: NCT04611048

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurological examination
Description: A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
Study: NCT03966976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow-up
Description: Conventional follow-up
Study: NCT00644098

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose and soybean oil
Study: NCT02328547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation capsules
Description: Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules prepared by OpenBiome, Medford, MA
Study: NCT02766387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.
Study: NCT04952441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Program
Description: Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RISE Program
Description: Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
Study: NCT01092299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Fast, 90mg, p.o. capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Moderate, 90mg, p.o. capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Slow, 90mg, p.o. capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: IR, 90 mg p.o. capsule
Study: NCT03434119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide
Description: Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
Study: NCT02777593

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device
Study: NCT03704818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5mg
Description: Dapagliflozin treatment taken daily for 4-weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo treatment taken daily for 4-weeks.
Study: NCT02523534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI images will be taken in conjunction with the clinically indicated cardiac MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: ECG readings will be taken prior to the participants clinically indicated procedure.
Study: NCT02813226

Intervention type: OTHER
Group type: OTHER
Intervention: Molecular Imaging
Description: Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
Study: NCT02873611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
Study: NCT00234975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
Study: NCT04025099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Cues
Description: The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT.
Study: NCT02873611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular ablation procedure
Study: NCT01168817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 plus Vardenafil
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with 3 tablets once daily for 4 weeks (Placebo)
Study: NCT01056224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
Study: NCT01387568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Infusion
Description: children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline Infusion
Description: children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
Study: NCT02528214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid therapy (prednisone/prednisolone)
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral corticosteroid therapy (prednisone/prednisolone)
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed.
Study: NCT01092299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: IR, 90 mg p.o. capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IR
Study: NCT02528214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed.
Study: NCT04025099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Cues
Description: The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity.
Study: NCT04598061

Intervention type: DRUG
Intervention: Dexmedetomidine IV
Description: Dexmedetomidine IV
Study: NCT02528214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed.
Study: NCT01234506

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside
Description: SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: secoisolariciresinol diglucoside
Description: SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
Study: NCT06380231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kangaroo mother care (KMC)
Description: Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index.
Study: NCT03249623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Caresystem
Description: The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
Study: NCT00749151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling
Description: First time callers to telephone help line agreed to one year follow-up on smoking cessation.
Study: NCT01764984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using parapatellar approach and postero-stabilized implants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
Study: NCT03220191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: palbociclib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: rabeprazole as PPI
Study: NCT04216108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy (23G gauge needle)
Description: Vitrectomy surgery with 23G gauge needle technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy (27G gauge needle)
Description: Vitrectomy surgery with 27G gauge needle technique
Study: NCT01753193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
Study: NCT04612361

Intervention type: OTHER
Intervention: insommnia severity index questionnaire
Description: insomnia severity index questionnaire and scoring system

Intervention type: OTHER
Intervention: insommnia severity index questionnaire
Description: insomnia severity index questionnaire and scoring system

Intervention type: OTHER
Intervention: insommnia severity index questionnaire
Description: insomnia severity index questionnaire and scoring system
Study: NCT03273439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS, without stimulation
Study: NCT02431039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEOSORB PLUS
Description: Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEOSORB
Description: Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
Study: NCT01092299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ER/MR
Study: NCT01472809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYGK1
Description: ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
Study: NCT00959387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction TP chemotherapy
Description: 3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Description: Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.